Phase 1/2a clinical trial of BI-1206, an anti-CD32b (FcgRIIB) antibody, in combination with pembrolizumab in subjects with advanced solid tumors previously treated with anti-PD-1/PD-L1

被引：0
|
作者：
Carneiro, Ana
Yachnin, Jeffrey
Aljumaily, Raid
Abel, Edvard
Falchook, Gerald Steven
Ji, Yan
Borggren, Marie
Martensson, Linda
Gertsson, Susanne
Karlsson, Ingrid
Teige, Ingrid
Tehranchi, Ramin
Wallin, Johan Erik
Chisamore, Michael Jon
Frendeus, Bjorn
McAllister, Andres
机构：
[1] Skane Univ Hosp, Dept Hematol Oncol & Radiat Phys, Comprehens Canc Ctr, Lund, Sweden
[2] Karolinska Comprehens Canc Ctr, Stockholm, Sweden
[3] OU Hlth Stephenson Canc Ctr, Oklahoma City, OK USA
[4] Sahlgrens Univ Hosp, Gothenburg, Sweden
[5] HealthONE, Sarah Cannon Res Inst, Denver, CO USA
[6] Hlth Partners, St Paul, MN USA
[7] BioInvent, Lund, Sweden
[8] Merck & Co Inc, Rahway, NJ USA
[9] BioInvent Int, Lund, Sweden
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2593
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Anti PD-1 (nivolumab, pembrolizumab) or anti PD-L1 (atezolizumab) versus docetaxel for previously treated patients with advanced NSCLC: A meta -analysis.
    Des Guetz, Gaetan
    Landre, Thierry
    Nicolas, Patrick
    Vergnenegre, Alain
    Chouaid, Christos
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [22] A phase 1 study of MEDI4736, an anti PD-L1 antibody, in patients with advanced solid tumors.
    Lutzky, Jose
    Antonia, Scott Joseph
    Blake-Haskins, Andy
    Li, Xia
    Robbins, Paul B.
    Shaiabl, Aiman M.
    Vasseill, Jim
    Ibrahim, Ramy A.
    Khleif, Samir
    Segal, Neil Howard
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [23] 17-BI-1206-02 Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to Fcgriib, in Combination with Rituximab in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or Is Refractory to Rituximab
    Jerkeman, Mats
    McAllister, Andres
    Roos, Carl
    Andersson, Marie Lindell
    Karlsson, Ingrid
    Borggren, Marie
    Abrisqueta, Pau
    Carneiro, Ana
    Cordoba, Raul
    Hagberg, Hans
    Mercadal, Santiago
    Teige, Ingrid
    Frendeus, Bjorn
    BLOOD, 2020, 136
  • [24] Ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients with advanced solid tumours
    Manish R. Patel
    Melissa Johnson
    Ira Winer
    Hendrik-Tobias Arkenau
    Natalie Cook
    Vanessa Samouëlian
    Raid Aljumaily
    Shigehisa Kitano
    Christine Duffy
    Miaomiao Ge
    Mabrouk Elgadi
    Lillian L. Siu
    Cancer Immunology, Immunotherapy, 73
  • [25] Ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients with advanced solid tumours
    Patel, Manish R.
    Johnson, Melissa
    Winer, Ira
    Arkenau, Hendrik-Tobias
    Cook, Natalie
    Samouelian, Vanessa
    Aljumaily, Raid
    Kitano, Shigehisa
    Duffy, Christine
    Ge, Miaomiao
    Elgadi, Mabrouk
    Siu, Lillian L.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (05)
  • [26] A phase Ia/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumors
    Deva, S.
    Lee, J-S.
    Lin, C-C.
    Yen, C-J.
    Millward, M.
    Chao, Y.
    Keam, B.
    Jameson, M.
    Hou, M-M.
    Kang, Y-K.
    Markman, B.
    Lu, C-H.
    Rau, K-M.
    Lee, K-H.
    Horvath, L.
    Friedlander, M.
    Hill, A.
    Wu, J.
    Hou, J.
    Desai, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [27] Bispecific anti-PD-1/CTLA-4 antibody for advanced solid tumors
    Perez-Santos, Martin
    PHARMACEUTICAL PATENT ANALYST, 2020, 9 (05) : 149 - 154
  • [28] Combination of MEDI0680, an anti-PD-1 antibody, with durvalumab, an anti-PD-L1 antibody: A phase 1, open-label study in advanced malignancies
    Hamid, O.
    Chow, L. Q.
    Sanborn, R. E.
    Marshall, S.
    Black, C.
    Gribbin, M.
    McDevitt, J.
    Karakunnel, J. J.
    Gray, J. E.
    ANNALS OF ONCOLOGY, 2016, 27
  • [29] Retreatment with anti-PD-1 antibody in non-small cell lung cancer patients previously treated with anti-PD-L1 antibody
    Fujita, Kohei
    Yamamoto, Yuki
    Kanai, Osamu
    Okamura, Misato
    Hashimoto, Masayuki
    Nakatani, Koichi
    Sawai, Satoru
    Mio, Tadashi
    THORACIC CANCER, 2020, 11 (01) : 15 - 18
  • [30] Multifunctionality of CD8+ T cells and PD-L1 expression as a biomarker of anti-PD-1 antibody efficacy in advanced melanoma
    Manabe, Keiko
    Yamasaki, Osamu
    Nakagawa, Yuki
    Miyake, Tomoko
    Udono, Heiichiro
    Morizane, Shin
    JOURNAL OF DERMATOLOGY, 2021, 48 (08): : 1186 - 1192
12345